Aldesleukin

Tyrosine Kinase Inhibitor
DB00041
Approved Indication

For treatment of adults with metastatic renal cell carcinoma.

3 Targets
0 Resistance Mutations
0 References
3D Structure No structure available
No co-crystal structure available
Mechanism of Action

Aldesleukin binds to the IL-2 receptor which leads to heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains, activation of the tyrosine kinase Jak3, and phosphorylation of tyrosine residues on the IL-2R beta chain. These events led to the creation of an activated receptor complex, to which various cytoplasmic signaling molecules are recruited and become substrates for regulatory enzymes (especially tyrosine kinases) that are associated with the receptor. These events stimulate growth and differentiation of T cells.

Details
DrugBank ID DB00041 ↗
Approval Date 1992-05-05
Molecular Weight — g/mol
Drug Class Tyrosine Kinase Inhibitor
ATC Codes L03AC01
Synonyms Interleukin-2 aldesleukin, Interleukin-2(2-133),125-ser